Press release
Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Advanced Non-Squamous & Squamous NSCLC Research. Learn more about our innovative pipeline today! @ Advanced Non-Squamous & Squamous NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Non-Squamous & Squamous NSCLC Pipeline Report
* June 2024:- Summit Therapeutics - A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi).
* June 2024:- AstraZeneca - The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC greater than or equal to 50%) and without actionable genomic alterations.
* June 2024:- AbbVie - A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
* June 2024:- Arcus Biosciences Inc. - A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.
* June 2024:- Genelux Corporation - A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance.
* June 2024:- Boehringer Ingelheim- Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations.
* June 2024:- Mabscale LLC -BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin Registered and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin Registered .
* DelveInsight's Advanced Non-Squamous & Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 11+ pipeline therapies for Advanced Non-Squamous & Squamous NSCLC treatment.
* The leading Advanced Non-Squamous & Squamous NSCLC Companies such as Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
* Promising Advanced Non-Squamous & Squamous NSCLC Therapies such as Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine) , and others.
Stay informed about the cutting-edge advancements in Advanced Non-Squamous & Squamous NSCLC Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Non-Squamous & Squamous NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Profile
* Erfonrilimab: Jiangsu Alphamab Biopharmaceuticals
KN-046 (Erfonrilimab) is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being evaluated under the Phase III clinical trial for the treatment of Advanced Squamous Non-small Cell Lung Cancer.
* Pyrotinib: Jiangsu HengRui Medicine
Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from advanced non-squamous NSCLC.
Learn more about Advanced Non-Squamous & Squamous NSCLC Drugs opportunities in our groundbreaking Advanced Non-Squamous & Squamous NSCLC Research and development projects @ Advanced Non-Squamous & Squamous NSCLC Unmet Needs [https://www.delveinsight.com/sample-request/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Non-Squamous & Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Subcutaneous
* Intravitreal
* Intramuscular
Advanced Non-Squamous & Squamous NSCLC Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Advanced Non-Squamous & Squamous NSCLC Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Non-Squamous & Squamous NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Non-Squamous & Squamous NSCLC Companies and Drugs
* Ribon Therapeutics Inc.: RBN-2397
* Summit Therapeutics:- AK112 Injection
* Jiangsu HengRui Medicine Co., Ltd.:- Pyrotinib/Docetaxel
* Sanofi:- SAR408701 (Tusamitamab ravtansine)
* Shanghai Shengdi Pharmaceutical Co., Ltd:- Adebrelimab+SHR-8068+Pemetrexed+Carboplatin
Scope of the Advanced Non-Squamous & Squamous NSCLC Pipeline Report
* Coverage- Global
* Advanced Non-Squamous & Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
* Advanced Non-Squamous & Squamous NSCLC Therapies- Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine), and others.
* Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Non-Squamous & Squamous NSCLC Pipeline on our website @ Advanced Non-Squamous & Squamous NSCLC Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Advanced Non-Squamous & Squamous NSCLC: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Non-Squamous & Squamous NSCLC - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pyrotinib: Jiangsu HengRui Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Non-Squamous & Squamous NSCLC Key Companies
* Advanced Non-Squamous & Squamous NSCLC Key Products
* Advanced Non-Squamous & Squamous NSCLC- Unmet Needs
* Advanced Non-Squamous & Squamous NSCLC- Market Drivers and Barriers
* Advanced Non-Squamous & Squamous NSCLC- Future Perspectives and Conclusion
* Advanced Non-Squamous & Squamous NSCLC Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3549205 • Views: …
More Releases from ABNewswire
Monport Strengthens Global Position with Launch of GM Pro Fiber and Reno CO2 Las …
The laser engraving industry is entering a new era of precision and performance with the launching of the GM Pro Fiber Laser Engraver Series [https://monportlaser.com/collections/gm-pro-fiber-laser-machine?sca_ref=5825031.wJzNqLroZf] and the Reno Desktop CO2 Laser Engraver Series [https://monportlaser.com/collections/reno-series?sca_ref=5825031.wJzNqLroZf]. Developed by Monport Laser, these next-generation laser engraving systems are engineered to meet the diverse needs of industrial manufacturers, small businesses, and creative professionals worldwide.
"Our mission is to make advanced engraving technology more accessible without compromising…
New York Real Estate Attorney Natalia A. Sishodia Outlines Strategies to Avoid N …
New York real estate attorney Natalia A. Sishodia (https://sishodia.com/how-to-avoid-the-nyc-transfer-tax/) of Sishodia PLLC is providing guidance for property buyers and sellers facing New York City's complex and costly transfer taxes. As real estate transactions in the city continue to involve significant tax burdens, understanding how to minimize these expenses is essential. Natalia A. Sishodia, a New York real estate attorney, emphasizes the importance of early planning and proper structuring to reduce…
New Jersey DUI Lawyer Rachel Kugel Outlines Insurance Consequences Following DUI …
A DUI conviction in New Jersey carries more than just legal penalties-it triggers significant financial repercussions, particularly with auto insurance. New Jersey DUI lawyer Rachel Kugel (https://thekugellawfirm.com/what-to-know-about-dui-car-insurance/) of The Kugel Law Firm breaks down the real-world insurance consequences that follow a DUI conviction, providing clear insight into the cost implications drivers face after such charges.
New Jersey DUI lawyer Rachel Kugel emphasizes that DUI convictions result in immediate and long-lasting effects…
Vinz Technologies Launches DiaryIt - A New Journal App That Turns Daily Entries …
Image: https://www.abnewswire.com/upload/2025/09/f832095ddc99a63a8f219d4ebbef237a.jpg
Vinz Technologies has announced the launch of DiaryIt, a new diary app [https://play.google.com/store/apps/details?id=app.vinztech.diaryit] now available on both iOS and Android. Designed as a powerful and private digital companion, DiaryIt transforms everyday journaling into personalized monthly stories, offering users a secure, creative, and insightful way to record their lives.
A Modern Take on Journaling
DiaryIt is a full-featured journal app [https://apps.apple.com/us/app/diaryit-daily-diary-journal/id6747474514] and personal diary built to help users record thoughts, emotions, and…
More Releases for Squamous
Forecasting the Future: Advanced Non-Squamous and Squamous NSCLC Market 2032 and …
The latest competent intelligence report published by CoherentMI with the title "An Increase in Demand and Opportunities for Global Advanced Non-Squamous and Squamous NSCLC Market 2025" provides a sorted image of the Advanced Non-Squamous and Squamous NSCLC industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact…
Squamous Cell Carcinoma Pipeline Insights Report | DelveInsight
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights…
Advanced Non-Squamous and Squamous NSCLC Market Size, Share, Emerging Trends, Fo …
According to a new report published by CoherentMI The advanced non-squamous and squamous NSCLC market is estimated to be valued at USD 10.89 Bn in 2024 and is expected to reach USD 16.58 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031.
Most recent Report, named "Advanced Non-Squamous and Squamous NSCLC Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI…
Best Statistical Advanced Non-Squamous and Squamous NSCLC Market Growth Set to S …
The latest competent intelligence report published by CoherentMI with the title "An Increase in Demand and Opportunities for Global Advanced Non-Squamous and Squamous NSCLC Market 2024" provides a sorted image of the Advanced Non-Squamous and Squamous NSCLC industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact…
Squamous Cell Carcinoma Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Squamous Cell Carcinoma Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research.…
